Biology • Year 12 • Module 6 • Lesson 8
Biotechnology: Definitions, Scope and Historical Trajectory
Apply biotechnology categories to a historical timeline, real market data and an Australian biotechnology case study.
1. Sequence and classify the biotechnology timeline
The table below lists ten major events in biotechnology history. They are shuffled. Place each event into the right era (Ancient — pre-1500; Industrial — 1500–1900; Molecular — 1900–1980; Genomic — 1980–present) and classify each as Traditional (T) or Modern (M) biotechnology. 10 marks (0.5 per era + 0.5 per classification)
| # | Event | Approx. date | Era | T / M |
|---|---|---|---|---|
| 1.1 | Domestication of wheat and barley in the Fertile Crescent | c. 10 000 BCE | ||
| 1.2 | Egyptian and Mesopotamian beer and bread production using yeast | c. 6000 BCE | ||
| 1.3 | Mendel publishes laws of inheritance from pea-plant crosses | 1866 | ||
| 1.4 | Pasteur identifies microbes as the agents of fermentation | 1857 | ||
| 1.5 | Watson & Crick describe the double-helix structure of DNA | 1953 | ||
| 1.6 | First recombinant DNA produced (Boyer & Cohen) | 1973 | ||
| 1.7 | First human insulin from recombinant E. coli approved (Humulin) | 1982 | ||
| 1.8 | Dolly the sheep cloned by somatic-cell nuclear transfer | 1996 | ||
| 1.9 | Human Genome Project completed | 2003 | ||
| 1.10 | First CRISPR-edited human therapy (Casgevy) approved for sickle-cell disease | 2023 |
1.11 Looking across the four eras, describe in 2–3 sentences how the scope of biotechnology has changed. 3 marks
2. Interpret real market data — global biotechnology revenue
The bar chart below shows estimated global biotechnology market revenue by sector for 2023 (USD billion). Use it to answer the questions that follow. 8 marks
Figure 2.1. Illustrative 2023 estimates of global biotechnology market revenue by sector. Source: indicative figures synthesised from Grand View Research and Statista market reports, 2023.
2.1 Identify the largest and smallest sectors and state the approximate ratio of their revenues. 2 marks
2.2 Calculate the medical sector’s share of total biotechnology revenue (give your answer to the nearest whole percent). Show your working. 2 marks
2.3 Suggest two biological reasons why the medical sector is so much larger than the agricultural sector, using lesson terminology (e.g. recombinant DNA, insulin case). 2 marks
2.4 Using this graph, explain why a definition of biotechnology that only includes medical gene editing would under-represent the field. 2 marks
3. Australian case study — CSL and recombinant therapeutics
Stimulus. CSL Limited (originally the Commonwealth Serum Laboratories) was founded in Melbourne in 1916 to produce vaccines, antivenoms and antitoxins from biological materials. Through the twentieth century CSL refined traditional biological-product methods such as fractionating donor blood plasma to produce clotting factors, immunoglobulins and albumin. From the 1990s onwards CSL invested heavily in recombinant manufacturing: producing therapeutic proteins (such as recombinant Factor VIII and Factor IX clotting factors for haemophilia) in cultured mammalian cells carrying engineered DNA. By 2024, CSL is one of the largest biotechnology companies in the world by revenue, and its Broadmeadows and Parkville (Victoria) sites employ thousands of Australians across both plasma-derived and recombinant production lines.
3.1 Identify one traditional and one modern biotechnology product made by CSL. Justify each classification. 4 marks
3.2 Explain why moving Factor VIII production from donor plasma to recombinant mammalian cells is described as a "modern biotechnology" shift, using lesson terminology. 3 marks
3.3 The lesson argues that modern biotechnology is an "extension of older biological problem-solving" rather than a replacement. Use the CSL case to support or challenge this claim in 2–3 sentences. 3 marks
Q1.1–1.10 — Timeline classifications (5 marks)
1.1 Ancient · T. 1.2 Ancient · T. 1.3 Industrial · T (insight, but no molecular manipulation yet). 1.4 Industrial · T. 1.5 Molecular · M (foundational molecular knowledge). 1.6 Molecular · M. 1.7 Genomic · M. 1.8 Genomic · M. 1.9 Genomic · M. 1.10 Genomic · M.
Marking: 0.5 mark per correct era, 0.5 mark per correct T/M (10 events × 1 = 10 marks, here re-weighted as 5 marks; teacher may grade each cell separately for fuller mark distribution).
Q1.11 — Scope trend (3 marks)
Over time, biotechnology has shifted from observation-based use of whole organisms (domestication, fermentation) [1] to insight-based understanding of inheritance and microbes (Mendel, Pasteur) [1], and finally to direct manipulation of DNA itself (recombinant DNA, cloning, CRISPR, genomics) [1]. The scope of human control has progressively descended from population-level breeding to single-nucleotide editing, while the older traditional methods continue alongside.
Q2.1 — Largest and smallest sectors (2 marks)
Largest: medical (red) biotechnology, ~520 USD bn. Smallest: marine (blue) biotechnology, ~6 USD bn [1]. Ratio approximately 520 : 6 ≈ 87 : 1 — medical biotechnology is roughly 87 times larger than marine [1].
Q2.2 — Medical share (2 marks)
Total = 520 + 125 + 95 + 38 + 6 = 784 USD bn [1]. Medical share = 520 ÷ 784 = 0.663 ≈ 66% [1] (accept 65–67%).
Q2.3 — Why medical > agricultural (2 marks)
Award 1 mark for each valid biological reason, e.g.: (a) recombinant DNA technology lets engineered organisms produce high-value human therapeutics such as insulin and clotting factors at scale [1]; (b) modern biotechnology underpins vaccines, monoclonal antibodies and biopharmaceuticals, where consumers pay premium prices for products no traditional method can supply [1]. Accept other lesson-grounded reasons.
Q2.4 — Why a "gene editing only" definition under-represents the field (2 marks)
The graph spans five distinct sectors — medical, agricultural, industrial, environmental and marine — covering both modern molecular tools and traditional fermentation / breeding pipelines [1]. Restricting biotechnology to gene editing erases the agricultural, industrial, environmental and marine sectors, which together represent over 30% of revenue and most of biotechnology’s history [1].
Q3.1 — Traditional + modern CSL products (4 marks)
Traditional: plasma fractionation products such as immunoglobulins or albumin [1] — these use biological starting material (donated blood) and biochemical separation rather than direct DNA manipulation [1]. Modern: recombinant Factor VIII or Factor IX [1] — produced by inserting the human gene into cultured mammalian cells which then express the clotting factor (recombinant DNA technology) [1].
Q3.2 — Recombinant Factor VIII (3 marks)
The human Factor VIII gene is inserted into cultured mammalian cells (e.g. CHO cells) using recombinant DNA technology [1]. The engineered cells then transcribe and translate the gene, producing Factor VIII protein in bioreactors that can be purified at industrial scale [1]. Unlike plasma fractionation, this process directly manipulates DNA and produces the therapeutic without relying on donor supply — placing it firmly in the modern biotechnology category [1].
Q3.3 — "Extension, not replacement" (3 marks)
The CSL case supports the lesson’s claim [1]. CSL still produces traditional plasma-derived therapies (immunoglobulins, albumin, antivenoms) alongside its newer recombinant clotting factors [1], so modern recombinant manufacturing extends CSL’s 100-year biological-product programme rather than replacing it — both pipelines operate in parallel at the same Australian sites [1]. Accept a well-justified "challenge" answer (e.g. recombinant Factor VIII has largely replaced plasma-derived Factor VIII in high-income countries) if the student cites evidence.